Untangling clinical data for Janus kinase (JAK) inhibitors for the treatment of Crohn’s disease has been challenging.
A team of investigators, including Tommaso Lorenzo Parigi, MD, Department of Biomedical Sciences, Humanitas University, Virginia Solitano, MD, Department of Biomedical Sciences, Humanitas University, Laurent Peyrin-Biroulet, MD, PhD, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, and Silvio Danese, MD, PhD, Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, recently examined the clinical data of 3 key and promising JAK inhibitors in this patient population.